Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology by Berasain, C. (Carmen) et al.
Pathological and virological findings in patients
with persistent hypertransaminasaemia of
unknown aetiology
C Berasain, M Betés, A Panizo, J Ruiz, J I Herrero, M-P Civeira, J Prieto
Abstract
Background—The histopathological spec-
trum and role of hepatitis viruses in cases
of hypertransaminasaemia of unknown
aetiology have not been correctly analysed
in a suYciently large number of patients.
Methods—We studied 1075 consecutive
patients referred for liver biopsy because
of elevation of alanine aminotransferase
(ALT) levels for more than six months.
From this population we selected those
cases in whom the aetiology could not be
defined from clinical, biochemical, and
serological data obtained before biopsy. In
these patients liver biopsies were re-
viewed, and hepatitis B virus (HBV)-DNA
and hepatitis C virus (HCV)-RNA were
assayed in serum by polymerase chain
reaction (PCR). Serum hepatitis G virus
(HGV)-RNA was determined by PCR in
74 patients.
Results—Of 1075 patients studied, the
cause of the increased serum ALT levels
remained elusive after appropriate testing
in 109 patients (10.1%). Liver biopsies
from these patients showed non-specific
changes in 32.7% of cases, non-alcoholic
steatohepatitis (NASH) in 15.8%, and
chronic hepatitis or cirrhosis in 51.5%.
HBV-DNA and/or HCV-RNA was detected
more frequently in cryptogenic liver dis-
ease than in healthy blood donors (26.7% v
3.4%; p<0.001). HGV-RNA was found in
only one patient. The proportion of cases
with detectable HBV-DNA or HCV-RNA
was 14.3% in patients with non-specific
changes or NASH, 30.7% in patients with
chronic hepatitis, and 61.5% in patients
with cirrhosis. Cirrhosis was found more
frequently in patients with positive HBV-
DNA and/or HCV-RNA in serum than in
those who tested negatively (p=0.005).
Conclusions—In our series, patients in
whom biochemical and serological data
did not determine the aetiology of the dis-
ease represented 10% of all cases referred
for liver biopsy for persistent elevation of
serum transaminases. Approximately 50%
of patients had chronic hepatitis or cir-
rhosis and the remainder had NASH or
non-specific changes. Occult viral infec-
tions were found in a high proportion of
cases in the first group and in a low
percentage of patients in the second.
(Gut 2000;47:429–435)
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In most patients with persistent abnormal liver
biochemistry, clinical data and serological tests
allow identification of the causative factor or
disease entity responsible for liver damage. The
aetiological search includes investigation of
alcohol abuse or exposure to drugs or other
toxins, detection of hepatitis B virus (HBV)
surface antigen (HBsAg) or antibodies against
hepatitis C virus (HCV), assays for autoanti-
bodies, ceruloplasmin, alpha1 antitrypsin,
serum ferritin, and transferrin saturation, and
study of other metabolic disorders or systemic
diseases (such as morbid obesity, diabetes with
deficient glycaemic control, or thyroid dysfunc-
tion) which can aVect the liver. However, in
some subjects with persistent alteration of liver
enzymes the cause of the disturbance cannot be
established on the basis of these clinical and
analytical data. These cases are referred to as
cryptogenic chronic liver disease. The preva-
lence and histopathological spectrum of this
entity have not been analysed in detail. In our
study, we investigated the histological findings
and implication of hepatitis viruses in cases
referred for liver biopsy as a result of persistent
elevation of transaminases in whom clinical,
biochemical, and serological testing prior to
histological sampling could not define the aeti-
ology of the disease.
The advent of the polymerase chain reaction
(PCR) allowed detection of HBV-DNA or
HCV-RNA in patients who lacked HBsAg or
anti-HCV antibodies.1–4 However, the signifi-
cance and prevalence of occult viral infections
in cryptogenic liver disease remains controver-
sial. Thus while some studies have found 67%
of HCV-RNA in whole blood from subjects
with cryptogenic chronic hepatitis or cirrhosis,3
other investigators failed to detect HCV-RNA
in the liver5 or serum6 from these patients. In
contrast, while in some series HBV-DNA could
not be detected in the serum of HBV seroneg-
ative patients with cryptogenic hepatitis7 or cir-
rhosis, in other series it was found in
14–85%4 8–12 of such cases. The low number of
cases analysed in most reports, variability of
criteria used to categorise patients, together
with diVerences in techniques and material
tested, and the diversity in geographic origin of
the reported series, have contributed to our
lack of knowledge of the pathogenic role of
Abbreviations used in this paper: HBV, hepatitis B
virus; HCV, hepatitis C virus; HGV, hepatitis G virus;
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reverse transcription-PCR; HIV, human
immunodeficiency virus.
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known hepatitis viruses in cryptogenic liver
diseases. In addition, most studies on chronic
liver disease of unknown aetiology have fo-
cused on specific histopathological entities
(chronic hepatitis and/or cirrhosis) and not on
the broader spectrum of patients with hepatic
disease of unknown causes who are referred for
liver biopsy because of persistent abnormalities
of liver biochemistry.
In this study we analysed 1075 consecutive
patients who underwent liver biopsy because of
persistent abnormalities in liver enzymes. From
this group we selected those cases in whom
clinical, biochemical, and serological screening
before biopsy did not identify the aetiology of
the liver lesion. In these cases the biopsy was
reviewed blindly, and the role of occult
infection by HBV, HCV, and hepatitis G virus
(HGV) was established by determining HBV-
DNA, HCV-RNA, and HGV-RNA in serum
using PCR.
Material and methods
PATIENTS
Patients with liver disease of unknown cause
were identified among 1075 consecutive pa-
tients who underwent liver biopsy in our liver
unit between 1991 and 1997. They were iden-
tified as cases with a persistent increase in
alanine aminotransferase (ALT) (>1.5 times
the upper limit of normal on at least two diVer-
ent occasions over a minimum period of six
months) and who met the following criteria:
(1) absence of HBsAg and anti-HCV antibod-
ies in serum; (2) ferritin, alpha1 antitrypsin, and
ceruloplasmin levels within the normal range;
(3) antinuclear, antimitochondrial, and anti-
smooth muscle antibodies at a titre of <1/80;
(4) ethanol intake less than 80 g/day; (5)
absence of treatment with potentially hepato-
toxic drugs; (6) negative human immuno-
deficiency virus (HIV) serology; (7) absence of
decompensated diabetes, thyroid dysfunction,
morbid obesity (defined as body mass index
>35 kg/m2) or other systemic diseases which
might aVect the liver, including severe hyper-
lipidaemia (cholesterol or triglyceride serum
levels greater than 350 mg/dl); and (7) absence
of focal intrahepatic lesions or biliary abnor-
malities at ultrasonography.
Epidemiological data (previous history of
acute hepatitis, transfusion, intravenous drug
addiction, acupuncture, tattooing, etc), clinical
data (patient age, sex, body mass index (body
weight in kg/height in metres)), and biochemi-
cal parameters, including glucose, triglycer-
ides, cholesterol, and proteinogram were re-
corded. Fifty eight consecutive sex and age
matched healthy blood donors from the hospi-
tal blood bank were used as controls.
LIVER HISTOPATHOLOGY
Liver biopsies were reviewed by an independ-
ent pathologist who was blinded to the
serological and biochemical patient data.
Specimens were fixed in 10% neutral buVered
formalin and stained with haematoxylin and
eosin, trichrome, orcein, and periodic acid-
SchiV with diastase digestion for reticulin and
iron. DiVerent histological parameters were
evaluated including fibrosis, portal inflamma-
tion, piecemeal necrosis, lobular inflammation,
lobular necrosis, steatosis, cholestasis, bile duct
damage, sinusoidal dilation, and iron deposi-
tion. These histological features were graded as
absent, sparse-mild, or moderate-severe. Fibro-
sis was graded on a scale of absent, sparse-
mild, or severe bridging-cirrhosis. According to
these data, liver biopsies were classified into
three groups: (1) chronic hepatitis and cirrho-
sis according to international criteria13; chronic
hepatitis in turn was subclassified into mild
(lymphocytic inflammation in more than one
third of portal tracts, leaving the parenchymal
limiting plate preserved, with minimal intra-
acinous changes), moderate (dense inflamma-
tory portal infiltration with piecemeal necrosis
involving less than 50% of the circumference of
most portal tracts but still restricted to
periportal areas), or severe (piecemeal necrosis
in the periportal region involving more than
50% of the circumference of most portal tracts,
and along fibrous septa); (2) non-alcoholic
steatohepatitis (NASH): moderate-gross mac-
rovesicular fatty changes with hepatocyte
degeneration and ballooning (with or without
Mallory hyaline bodies) or fibrosis in zone
314 15; and (3) non-specific/minimal changes: a
variety of mild abnormalities including intra-
hepatocytic cholestasis, steatosis, sinusoidal
dilation, and mild lobular inflammation or
necrosis.
Immunoperoxidase staining for HBV surface
and core proteins was performed in liver sam-
ples of all PCR-B positive cases.
SEROLOGY
HBsAg, anti-HBc (IgG), and anti-HBs were
tested by standard ELISA kits (Cobas Core,
Roche, Madrid). Anti-HCV antibodies were
detected using the ELISA 3 test (Ortho-
Clinical Diagnostics GmbH, Germany). Anti-
HIV antibodies were tested by ELISA (Cobas
Core, Roche, Madrid). Antiendomysium anti-
bodies were tested using the indirect fluores-
cent antibody procedure (MARDX Diagnos-
tics, Inc., California, USA).
PCR ASSAY FOR HBV DNA
DNA was extracted from 200 µl of serum using
the High Pure Viral Nucleic Acid Kit
(Boehringer Mannheim, Mannheim, Ger-
many). Every extraction and PCR set included
12 samples: seven serum samples to be tested,
three water samples as negative controls to
detect cross contamination, and two positive
controls to establish sensitivity, corresponding
to two dilutions of serum from a HBsAg posi-
tive patient representing 300 and 30 HBV par-
ticles, respectively. Nested PCR was performed
using the following as primers: HBV-S1 (nt
222-241), HBV-S2 (nt 757-738), HBV-S3
(324-343), and HBV-S4 (707-688).16 Briefly,
half of the DNA volume was amplified for 36
cycles (95°C for 20 seconds, 60°C for 15
seconds, and 72°C for 25 seconds) followed by
a final extension at 72°C for 10 minutes in a
total reaction mixture of 30 µl containing 10
mM Tris HCl, pH 8.3, 1.5 mM MgCl2, 50 mM
KCl, 400 mM dNTP, 1.5 U of Taq polymerase
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(Boehringer Mannheim), and 0.15 mM of each
outer primer HBV-S1 and HBV-S2. The first
PCR product (1 µl) was mixed with 9 µl of the
reaction mixture (as described above) contain-
ing each of the inner primers HBV-S3 and
HBV-S4. A second round of PCR was
performed with the same protocol and the 10 µl
of reaction mixture were loaded on a 2% agar-
ose gel for electrophoresis. All precautions for
avoiding PCR contamination were followed
stringently. Each positive result was confirmed
by a second independent determination. DNA
from liver was extracted using the DNAzol
Reagent (Life Technologies, Gibco BRL,
Gaithersburg, USA). DNA (1 µg) was used for
amplification with the PCR protocol described
above. The sensitivity of the assay was 103
genome eq/ml.
CLONING AND SEQUENCE ANALYSIS
Positive samples were loaded after amplifica-
tion on a 2% agarose gel. Bands were excised
from the gel and DNA was purified using the
Geneclean II kit (Bio 101, Vista, California,
USA). Aliquots were cloned into the pCR2.1-
TOPO plasmid using the TOPO-TA cloning
kit (Invitrogen, Carlsbad, California, USA). At
least 10 white colonies were tested for the pres-
ence of the insert by PCR. Minipreps were
performed using the Qiaprep Spin Miniprep
kit (Qiagen, Hilden, Germany). A minimum of
five clones were sequenced with M13 primers
using the dRhodamine Terminator Cycle
Sequencing Ready Reaction Kit in an ABI
PRISM 310 Genetic Analyzer (PE Applied
Biosystems, Foster City, California, USA).
Bidirectional sequencing was performed to
confirm mutations. Sequences from each
patient were compared using the Clustal
program and each representative sequence was
compared for homology in the GenBank.
RT-PCR ASSAY FOR DETECTION OF HCV RNA
RNA was extracted from sera and liver using
the Ultraspec Reagent (Biotecx Laboratories,
Inc., Houston, Texas, USA). RT-PCR was per-
formed using primers from 5'UTR as de-
scribed previously.17
PCR ASSAY FOR DETECTION OF HGV RNA
RNA was extracted from sera using the
Ultraspec Reagent (Biotecx Laboratories, Inc.,
Houston, Texas, USA). HGV-RNA was de-
tected by RT-PCR using a commercial kit
(Hepatitis G Virus-Primer and Capture Probe
Set; Boehringer Mannheim).
STATISTICAL ANALYSIS
Fisher’s exact test was used to compare
proportions and the Student’s t test to compare
continuous variables. The Mann-Whitney U
test was used to compare non-parametric vari-
ables in independent samples. All statistical
tests were two tailed.
Results
PREVALENCE OF CRYPTOGENIC LIVER DISEASE
AMONG PATIENTS WHO UNDERWENT LIVER BIOPSY
BECAUSE OF PERSISTENT ALT ELEVATION
We investigated 1075 patients referred for liver
biopsy because of persistent (more than six
months) elevation of serum transaminases. In
966 cases (89.8%), clinical, biochemical, and
serological testing allowed identification of the
disease entity or aetiology of the process while
in 109 patients (10.1%) the cause of the
hepatic lesion was not identified before the liver
biopsy was performed, despite an appropriate
diagnostic work up (see material and meth-
ods). Of the 109 cases of liver disease of
unknown cause, serum samples from eight
patients were not available. Thus 101 patients
(71 male, 30 female, mean age 45.8 (13.5)
years) were included in the study.
HISTOPATHOLOGICAL FINDINGS IN CRYPTOGENIC
LIVER DISEASE
Liver biopsies from the 101 cases with
hypertransaminasaemia of unknown aetiology
included in the study were reviewed blindly by
the same pathologist. Examination of the liver
tissue showed non-specific changes in 33
subjects (32.7%) and NASH in 16 patients
(15.8%). All patients with NASH presented
moderate to severe steatosis in liver tissue while
in the group recorded as non-specific changes,
moderate to severe steatosis (simple fatty liver)
was observed in four cases and mild steatosis in
17 (other criteria for NASH are given in mate-
rial and methods). Chronic hepatitis was found
in 39 patients (38.6 %), being mild in 11 and
moderate/severe in 28. Cirrhosis was present in
13 subjects (12.9%). These diagnoses were
coincident with the initial report except that
four cases previously recorded as simple fatty
liver were included in the NASH group and
four cases diagnosed as minimal changes were
considered as mild chronic hepatitis after
histological review.
PREVALENCE OF HBV-DNA, HCV-RNA, AND
HGV-RNA IN CRYPTOGENIC LIVER DISEASE
The prevalence of HBV-DNA and/or HCV-
RNA was significantly higher in patients with
hepatic disease of unknown cause than in
healthy blood donors (26.7% v 3.4%;
p<0.001). HBV-DNA and HCV-RNA were
detected in the serum of 19 (18.8%) and nine
(8.9%) patients with cryptogenic disease,
respectively. One healthy blood donor was
HBV-DNA positive (1.7%) and another HCV-
RNA positive (1.7%). Only one patient and
none of the controls showed positivity for both
viral genomes (table 1). In the group of 966
cases (representing 89.9% of the total number
of 1075 patients studied) in which the aetiology
of the liver lesion was established by conven-
tional diagnostic tests, 96 (9.9%) had HBV
infection, 548 (56.7%) had HCV infection,
and 10 (1.03%) were infected by both HCV
and HBV. Therefore, occult HBV infection was
more prevalent than occult HCV infection
despite the fact that seropositive hepatitis C is
more prevalent than HbsAg positive liver
disease in our geographic area.
We tested 74 patients for the presence of
HGV-RNA: only one patient (1.3%) was found
to be positive. This patient was negative for
HBV-DNA and HCV-RNA. HGV-RNA was
not present in any of the healthy blood donors
tested.
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In five HBV-DNA positive and two HCV-
RNA positive subjects, investigation of these
viral sequences in serum was repeated in sam-
ples obtained on three or more occasions. In
three of the former group and in one of the lat-
ter, a positive PCR test was obtained in two or
more samples. These data indicate that in our
patients with positive HBV-DNA or HCV-
RNA, viral load was low and viraemia was
detectable only intermittently.
Four patients with cryptogenic cirrhosis
underwent orthotopic liver transplantation
(two who tested positive for serum HBV-DNA
and two who tested negative). In these four
cases we studied the presence of HBV-DNA
and HCV-RNA in the explanted liver and in
post-transplantation serum (1–28 weeks after
liver transplantation). HBV-DNA was detected
in the explanted liver only in the two cases who
were serum HBV-DNA positive before trans-
plantation. One of these patients continued to
have detectable HBV-DNA in serum after
transplantation. HCV-RNA was negative in
both post-transplantation serum and explanted
liver in all four cases.
MARKERS OF HEPATITIS VIRUS IN CRYPTOGENIC
LIVER DISEASE
The presence of anti-HBV antibodies was
tested in 98 patients. As shown in table 2
30.6% patients showed positivity for either
anti-HBc or anti-HBs, or both. Fifty per cent of
cases with positive serum HBV-DNA and
26.2% with negative HBV-DNA had positive
HBV antibodies. These diVerences were not
statistically significant. Interestingly, all HCV-
RNA positive cases showed negative anti-HBV
antibodies (table 2). These results (and the fact
that we found positivity for both HBV-DNA
and HCV-RNA in only one case) indicate that
HBV positive and HCV positive cases repre-
sent two serologically diVerentiated groups.
HBs and HBc proteins were investigated in
liver biopsies by immunohistochemistry. All
cases were found to be negative. Finally, it is
worth noting that for all viral markers (HCV-
RNA, HBV-DNA, and anti-HBV antibodies),
only 52 of 98 cases lacked serological signs of
contact with hepatitis viruses.
CLINICAL AND BIOCHEMICAL FINDINGS IN
CRYPTOGENIC LIVER DISEASE ACCORDING TO THE
PRESENCE OR ABSENCE OF HBV-DNA OR HCV-RNA
IN SERUM
We compared clinical and biochemical data
from patients with liver disease of unknown
cause and who were positive for HBV-DNA or
HCV-RNA with those in whom viraemia was
not detected. As shown in table 3, patients
from the first group were significantly older
(50.6 (14.3) v 43.9 (12.8) years; p=0.03) and
showed clinical signs of decompensated cir-
rhosis more frequently (25.9% v 5.4%;
p=0.007) than patients in whom both HBV-
DNA and HCV-RNA were negative. The
number of patients with dyslipaemia (elevated
serum cholesterol and/or triglyceride levels)
was significantly higher in patients without
detectable viraemia than in positive cases
(p=0.04), probably reflecting a higher pro-
portion of NASH among these patients. Also,
ALT levels were significantly higher in patients
who tested negative for HBV-DNA or HCV-
RNA than in cases with detectable viraemia,
but no significant diVerences in other clinical
and biochemical data (including glycaemia,
obesity, gamma globulin levels, presence of
low titres of autoantibodies, parenteral expo-
sure, or past history of acute hepatitis) were
observed. With respect to cases diagnosed as
NASH, none showed fasting glycaemia in
excess of 130 mg/dl, in only two patients did
serum cholesterol exceed 300 mg/dl, and in
only three cases were triglyceride levels greater
than 300 mg/dl with 332 mg/dl being the
highest value (patients with decompensated
diabetes, morbid obesity, and severe dyslipae-
mia were excluded from the category of
hypertransaminasaemia of unknown aeti-
ology). Antiendomysium antibodies were
tested in 64 patients from the first group and
in 10 from the second (cases with negative and
positive viraemia, respectively); the test was
negative in all cases, indicating a low percent-
age of occult coeliac disease in our series of
cryptogenic liver disease. There were no
significant diVerences in clinical or biochemi-
cal parameters between patients with positivity
for HBV-DNA and those with positivity for
HCV-RNA.
PREVALENCE OF HBV-DNA OR HCV-RNA IN THE
DIFFERENT HISTOPATHOLOGICAL FORMS OF LIVER
DAMAGE IN PATIENTS WITH CRYPTOGENIC LIVER
DISEASE
With regard to the prevalence of HBV-DNA or
HVC-RNA in the diVerent histopathological
forms of liver damage in patients with cryp-
togenic liver disease, viraemia was found in
14.3% of patients with NASH or non-specific
changes, in 30.7% of those with chronic hepa-
Table 1 Prevalence of HBV-DNA and HCV-RNA in
patients with cryptogenic liver disease (n=101) and in
healthy controls (n=58)
HBV-DNA/
HCV-RNA
Cryptogenic
(No (%))
Healthy controls
(No (%))
P/P 1 (1) 0
P/N 18 (17.8) 1 (1.7)
N/P 8 (7.9) 1 (1.7)
N/N 74 (73.3) 56 (96.5)
P, positive cases; N, negative cases.
Table 2 Presence of anti-HBc and anti-HBs antibodies in
patients with cryptogenic liver disease
HBV-DNA Anti-HBc Anti-HBs n
P P P 5
P P N 1
P N P 3
P N N 9*
P nt nt 1
N P P 14
N P N 2
N N P 5†
N N N 59‡
N nt nt 2*
P, positive cases; N, negative cases; n, number of cases; nt, not
tested.
*One patient in each group was HCV-RNA positive.
†One patient was vaccinated.
‡Seven patients were HCV-RNA positive and one patient was
HGV-RNA positive.
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titis, and in 61.5% of subjects with cirrhosis (fig
1). In patients with non-specific changes or
NASH, the prevalence of viraemia was not sig-
nificantly diVerent from that found in controls
(p=0.08). In contrast, in patients with chronic
hepatitis or cirrhosis, the percentage of cases
with positive HBV-DNA or HCV-RNA was
significantly higher than in healthy controls
(38.5% v 3.4%; p<0.001) or patients with
non-specific changes or NASH (38.5% v
14.3%; p=0.007). Cirrhosis was significantly
more prevalent in the group of patients with
detectable HBV-DNA or HCV-RNA than in
cases with negative viraemia (29.6% v 6.8%;
p=0.005) (table 3). No significant diVerences
in liver histopathology were found between
subjects with anti-HBV antibodies and those
without anti-HBV antibodies in serum.
SEQUENCE OF HBV IN PATIENTS WITH POSITIVE
HBV-DNA IN SERUM
The HBV fragment amplified by PCR com-
prised the immunodominant “a” determinant
of HBsAg as well as 383 nucleotides from the
polymerase gene. This fragment was cloned
and sequenced in 17 of the 19 HBV-DNA
positive patients. In all cases a minimum of five
clones per sample were analysed.
All HBV sequences corresponded to geno-
type A serotype adw2 (50% of samples) or to
genotype D serotype ayw (50% of samples).
No diVerences were found in clinical, bio-
chemical, or pathological findings in relation to
the HBV genotype present in serum.
Sequences in seven patients showed total
homology with wild-type sequences published
previously. In the remaining 10 patients at least
one nucleotide change was found, two of which
were associated with deletion of one and six
nucleotides, respectively, in some of the clones.
In eight of these patients two or three diVerent
HBV sequences were found. The observed
mutations caused at least one amino acid
change in both polymerase and HBsAg genes
in nine patients and one amino acid change in
the polymerase gene in the remaining patient.
In three cases the changes aVected the “a”
determinant.
Discussion
In patients who underwent liver biopsy because
of persistent alteration of liver biochemistry,
the aetiology of the liver lesion could not be
determined from clinical, biochemical, or sero-
logical data obtained prior to the biopsy in 10%
of cases. This value is similar to the reported
prevalences of 9.2% and 8.2% for cryptogenic
hypertransaminasaemia observed in other
European series.18 19
There is little information on the spectrum
of pathological liver changes which can be
found in patients with hypertransaminasaemia
of unknown aetiology.20 This is mainly because
most histological studies in large series of
patients were performed before the discovery
of hepatitis C. Most recent reports on cryp-
togenic chronic liver disease have focused on
cases with chronic hepatitis and/or
cirrhosis.6 21 22 In our work, only about half
(51.5%) of our patients had chronic hepatitis
or cirrhosis while the remaining patients
(48.5%) exhibited non-specific changes or
NASH. These two groups of pathological enti-
ties (chronic hepatitis or cirrhosis on the one
hand and non-specific changes or NASH on
the other) appear to correspond to diVerent
causes of liver damage as the prevalence of
HBV/HCV viraemia was found to be high in
the former group and low in the latter. Patients
who were found to have NASH on histological
examination entered the group of hyper-
transaminasaemia of unknown aetiology be-
cause the categorisation “cryptogenic” was
made without knowledge of the liver biopsy
results. Although NASH could be anticipated
in cases of morbid obesity, severe dyslipaemia,
or diabetes with deficient or deterioration in
glycaemic control, we considered these condi-
tions exclusion criteria for hypertransamina-
Table 3 Clinical, biochemical, and histological features of patients with cryptogenic liver
disease according to the presence of occult hepatitis viruses
HBV-DNA and/or
HCV-RNA positive
(n=27)
HBV-DNA and
HCV-RNA negative
(n=74) p Value
Age (y) 50.67 (14.34) 43.99 (12.84) 0.03
Sex (M/F) 19/8 52/22 >0.2
Risk factors 1
Transfusion 1/24 (4.2%) 4/67 (6%) >0.2
History of acute hepatitis 2/24 (8.3%) 13/57 (22.8%) >0.2
Anti-HBs and/or anti-HBc 9/25 (36%) 20/73 (27.4%) >0.2
Clinical symptoms 0.007
Decompensated cirrhosis 7 (25.9%) 4 (5.4%)
Non-specific symptoms 20 (74.1%) 70 (94.6%)
Dyslipaemia2 7 (25.9%) 36 (48.7%) 0.04
Hyperglycaemia 5 (7.4%) 12 (16.2%) >0.2
Obesity 9 (33.3%) 14 (18.9%) 0.2
Gamma globulin (g/dl)3 1.38 (0.46) 1.21 (0.3) 0.08
Liver function tests3
AST/GOT (UI/l) 38 (25.9) 32 (36.4) >0.2
ALT/GPT (UI/l) 52.5 (32.4) 72.8 (64.7) 0.007
No patients with mean ALT>1.5 normal 11 (40.7%) 56 (75.7%) 0.001
Alkaline phosphatase (UI/l) 185.2 (94.9) 190.8 (112) >0.2
GGT (UI/l) 81.1 (75.5) 109.5 (101.8) 0.08
Autoantibodies (ANA, ASMA) (<1/80) 5 (18.5%) 13 (17.6%) >0.2
Liver biopsy 0.01
Non-specific changes 5 (18.5%) 28 (37.8%)
NASH 2 (7.4%) 14 (18.9%)
Chronic hepatitis 12 (44.4%) 27 (36.5%)
Cirrhosis 8 (29.6%) 5 (6.8%)
Values are mean (SD) or number (%).
1Number of positive patients/number of patients studied.
2Levels of cholesterol and/or tryglicerides above the normal limit in at least two determinations.
3The individual numbers used to calculate the mean were the average for all determinations on
each patient (mean 5, range 2–24). Normal values: gamma globulin <1.34 g/dl; AST/GOT <25
UI/l; ALT/GPT <29 UI/l; alkaline phosphatase <207 UI/l; GGT <38 UI/l.
Figure 1 Percentage of patients with cryptogenic liver
disease and healthy controls who had detectable hepatitis B
virus-DNA and/or hepatitis C virus-RNA by polymerase
chain reaction in serum.NASH, non-alcoholic
steatohepatitis.
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saemia of unknown cause. Mild to moderate
metabolic disorders, as those present in our
cases of cryptogenic liver disease with NASH
(see results), are highly prevalent in the
population and are not generally considered as
a cause of liver dysfunction in the absence of
histological study.
DiVerent reports have indicated that low
level replication of HBV and/or HCV may play
a pathogenic role in a proportion of cases with
cryptogenic hepatitis or cirrhosis.2 3 8 9 Re-
cently, low levels of serum HBV-DNA were
detected in patients with HCV infection
lacking other serological HBV markers.4 In our
study, 27% of all cases with chronic hyper-
transaminasaemia of unknown aetiology were
positive for either HBV-DNA or HCV-RNA.
The presence of HBV-DNA in liver tissue in
two transplanted cases who tested positive for
HBV-DNA in a pretransplant serum sample
and the absence of the HBV genome in the liver
in two other cases who tested negative for
HBV-DNA in serum before transplantation
further support the implication of HBV in
cryptogenic chronic liver damage in cases
where HBV-DNA is detected in serum by PCR
techniques. It has been reported that detection
of HCV-RNA in whole blood is more sensitive
than serum assays3; on the other hand, it has
been shown that HBV-DNA can be found in
liver tissue in patients in whom viral sequences
are not detectable in serum, even using
sensitive techniques.4 23 24 Thus it seems possi-
ble that participation of known hepatitis viruses
in the aetiology of cryptogenic chronic hepati-
tis and cryptogenic cirrhosis might be higher
than that observed in the present study.
However, it should be noted that our results
relate to a Mediterranean country with a high
prevalence of hepatitis viruses in the general
population and may not be applicable to other
parts of the world, such us north west Europe,
where hepatitis B and C are much less
common.
Importantly, when pathological and virologi-
cal data (which were performed blindly by
independent observers) were pooled, we found
that most patients (74%) with positive viraemia
(HBV-DNA or HCV-RNA) had chronic hepa-
titis or cirrhosis. As shown in fig 1, there was a
progressive increase in the prevalence of virae-
mia as the severity of the liver lesion increased,
with values of 3.4% in healthy blood donors,
14.3% in patients with NASH or non-specific
changes, 30.7% in those with chronic hepatitis,
and 61.5% in subjects with cirrhosis. These
data support the specificity of our findings and
strongly suggest the participation of occult
HBV and HCV infections (HBV being more
prevalent than HCV) in the aetiology of
cryptogenic hepatitis and cirrhosis. In patients
with chronic hypertransaminasaemia of un-
known aetiology the presence of viral genomes
(HBV-DNA or HCV-RNA) in serum appears
to predict a more severe disease. Thus patients
with cryptogenic liver disease with positive
viraemia had a higher prevalence of cirrhosis
(29.6%) than those cases who tested negative
for HBV-DNA and HCV-RNA (6.8%,
p=0.005). Also, the former group of patients
exhibited signs of decompensated cirrhosis
more frequently than those with undetectable
viraemia (table 3). These data are in accord-
ance with reports showing a more aggressive
course in cryptogenic cirrhosis when viral
sequences can be detected in serum compared
with patients who tested negative.3 Occult
HBV infection has also been found to correlate
significantly with cirrhosis in HCV infected
patients suggesting that occult replication of
HBV at low levels can accelerate the evolution
to cirrhosis in patients with chronic HCV
infection.4
Although low level replication of HBV may
favour progression of the liver lesion the patho-
genic relevance of antibodies to HBV in the
absence of detectable HBV-DNA remains
obscure. In fact, among patients with negative
viraemia, there were no significant diVerences
in liver histopathology between those with
anti-HBV antibodies and those who tested
negative.
A previous report has suggested that HBV
genotype D is the “surviving” genotype after
clearance of HbsAg.25 In our series, patients
with cryptogenic liver disease were infected
with HBV genotype D or HBV genotype A in a
similar proportion and there was no correlation
between genotype and clinical or pathological
data. Sequencing of the amplified fragment of
HBV-DNA showed mutations in 10 of the 17
cases analysed; these changes aVected the “a”
determinant of HBsAg in only three cases. It
seems therefore that changes in other parts of
the HBV genome may be responsible for
persistent and low grade replication of HBV in
these cases with occult viral infection. In fact,
deletions in the X gene have been suggested to
be responsible for the low level of replication in
HBsAg negative patients with positive
viraemia.12 26
HGV was present in only one case, indicat-
ing that this virus is not involved in cryptogenic
chronic liver disease. This is in accordance with
previous data which do not support the
participation of HGV in cryptogenic
hepatitis.27–29 Some reports have suggested that
about 10% of cases of cryptogenic chronic
hepatitis have features typical of autoimmune
hepatitis but lack autoantibodies.30 Autoimmu-
nity could be implicated in cases with cryp-
togenic chronic hepatitis or cirrhosis with
negative viraemia but the high percentage of
HBV-DNA or HCV-RNA positive cases in this
study calls for caution when considering
corticosteroid treatment in cryptogenic hepati-
tis. In these cases PCR tests for HBV-DNA and
HCV-RNA should be performed before initia-
tion of therapy. Although treatment with
antiviral agents could be considered for cases
with positive viraemia, controlled studies are
needed to establish whether these patients can
benefit from this form of therapy.
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